Potential use of psilocybin drugs in the treatment of depression
Expert Opinion on Emerging Drugs – October 02, 2023
Source: OpenAlex
Summary
A potent Hallucinogen, Psilocybin, is showing early promise as a groundbreaking medicine for major depressive disorder and treatment-resistant depression. Initial clinical trials, part of emerging Psychedelics and Drug Studies, suggest rapid symptom relief. However, this unique alkaloid, often produced via chemical synthesis, requires extensive randomized controlled trials in large Phase III studies. Such rigorous evaluation is vital to confirm its safety and efficacy, paving the way for its acceptance within psychiatry as a transformative treatment for depression.
Abstract
Clinical phase I-II trials published to date reported promising results for psilocybin in the treatment of patients with major depressive disorder and treatment-resistant depression, in a relatively short time after administration. However, before psilocybin is approved for use and administered to patients with depression, the results of large ongoing phase III clinical trials are needed to confirm its efficacy and safety and to change the way it is perceived by physicians and patients.